NorCal-Gene Therapy and Research

norcaloa.com

NorCal Open Access Publications is an international open access journals publisher based at California, United States of America. All our Journals follow peer review process and publish manuscripts on an open access platform. Our Journals fall in the scope of Medical, Clinical, Life sciences, Pharmaceutical and Engineering.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

news image

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More

CELL AND GENE THERAPY

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More

CELL AND GENE THERAPY

ITOLERANCE TO COLLBORATE WITH LYGENESIS FOR JOINT RESEARCH

iTolerance | July 01, 2022

news image

iTolerance, Inc., an early-stage privately held regenerative medicine company developing technology to enable organoid, tissue, and cell therapy, announced entering into a joint collaboration with LyGenesis, Inc., a clinical-stage biotechnology company with an organ regeneration technology platform. The joint collaboration is aimed at evaluating the potential of iTOL-201, a product candidate being developed combining LyGenesis' LYG-LIV-100 liver cell therapy and iTolerance's SA FasL micr...

Read More

INDUSTRIAL IMPACT

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

news image

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More
news image

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More
news image

CELL AND GENE THERAPY

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More
news image

CELL AND GENE THERAPY

ITOLERANCE TO COLLBORATE WITH LYGENESIS FOR JOINT RESEARCH

iTolerance | July 01, 2022

iTolerance, Inc., an early-stage privately held regenerative medicine company developing technology to enable organoid, tissue, and cell therapy, announced entering into a joint collaboration with LyGenesis, Inc., a clinical-stage biotechnology company with an organ regeneration technology platform. The joint collaboration is aimed at evaluating the potential of iTOL-201, a product candidate being developed combining LyGenesis' LYG-LIV-100 liver cell therapy and iTolerance's SA FasL micr...

Read More
news image

INDUSTRIAL IMPACT

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More